New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for infusion - 2 g - active: ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 298.25mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy);   - powder for injection - 250 mg - active: ceftriaxone sodium 298.25mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy)  

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd);   - powder for injection - 500 mg - active: ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd)  

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd);  ;   - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)    

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd);  ;   - powder for injection - 2 g - active: ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)    

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - ceftriaxone as sodium - powder for solution for inj/inf - ceftriaxone as sodium 1000 mg/vial - ceftriaxone - ceftriaxone - * ceftriaxone-fresenius is indicated for the treatment of the following infections in adults and children including term neonates (from birth) :- bacterial meningitis- community acquired pneumonia- hospital acquired pneumonia- acute otitis media- intra-abdominal infections- complicated urinary tract infections (including pyelonephritis)- infections of bones and joints- complicated skin and soft tissue infections- gonorrhoea- syphilis- bacterial endocarditis* ceftriaxone-fresenius may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii)) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infectionsin the management of neutropenic patients with fever that is suspected to be due to a bacterial infectionin the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above* ceftriaxone-fresenius should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.* consideration should be given to official guidelines on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g in 50 ml - ceftriaxone for injection and dextrose injection is indicated for the treatment of the following infections when caused by susceptible bacteria. lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens . skin and skin structure infections caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes, viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii 1, pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis 1 or peptostreptococcus species. complicated and uncomplicated urinary tract infections caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae . pelvic inflammatory disease caused by neisseria gono

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused b

Israel - English - Ministry of Health

pharmalogic ltd - ceftriaxone as sodium - powder for solution for inj/inf - ceftriaxone as sodium 1 g/vial - ceftriaxone - ceftriaxone - ceftriaxone panpharma is indicated for the treatment of the following infections in adults and children including term neonates (from birth):- bacterial meningitis- community acquired pneumonia- hospital acquired pneumonia- acute otitis media- intra-abdominal infections- complicated urinary tract infections (including pyelonephritis)- infections of bones and joints- complicated skin and soft tissue infections- gonorrhoea- syphilis- bacterial endocarditisceftriaxone panpharma may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infections- in the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone- susceptible bacterial infection- in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above ceftriaxone panpharma should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

samson medical technologies, llc - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 100 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection is indicated for the treatment of the following infections when caused by susceptible bacteria: lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens . skin and skin structure infections caused by staphylococcus aureus, staphylococcus epi